MB Venture Partners
Gary Stevenson, Co-Founder and Managing Partner
Gary Stevenson co-founded MB Venture Partners in 2001 after six years in healthcare investment banking and equity research. At MBVP, he has raised $120 million in committed capital to four funds and invested in more than 50 start-ups, most of which are focused on product solutions for musculoskeletal disease. He also spent seven years in a variety of general management roles with Abbott Laboratories. Gary holds an undergraduate degree in accounting from the University of Missouri. He also received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. He is a certified public accountant and a chartered financial analyst. Gary is a board member or observer for several MBVP portfolio companies. Medtronic, Smith + Nephew, Zimmer Biomet, and Wright Medical have each acquired MBVP-funded start-ups. This will be his 18th year to host the MNVC.
Charles Hamilton, Director, Healthcare Investment Banking
Charles Hamilton is a Director in the Piper Sandler healthcare investment banking group and a senior partner of the medical technology team. Hamilton has 20 years of healthcare investment banking and capital markets experience, and has completed over 75 M&A and capital markets transactions on behalf of his medical technology clients at Piper Sandler. Hamilton joined Piper Sandler in 2008 from Thomson Financial, where he was a senior investor relations consultant to publicly traded companies. Previously, Hamilton was a member of the Chicago Board of Trade and an open outcry market maker for commodities options contracts. Earlier in his career, he conducted research in gene therapies for vascular disease at The University of Chicago Hospitals Section of Vascular Surgery. Hamilton graduated from The University of Chicago with a bachelor’s degree in cell and molecular biology, and received a Master of Business Administration with concentrations in analytic finance and accounting from The University of Chicago Booth School of Business.
Patrick O’Donnell, President & CEO
Ian Helmar, Founder & V.P. of Research and Development
NanoHive Medical, LLC (formerly HD LifeSciences) is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company’s proprietary, biomimetic Soft Titanium® technology clearly distinguishes their products in the $1.9B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences. NanoHive Medical is located in Woburn, Massachusetts U.S.A
Kevin Rocco, Founder and CEO
Jeff Baird, Chief Financial Officer
Biorez is a New Haven, CT-based medical device start-up focused on advancing the healing of soft tissues using its proprietary BioBrace technology. The company has pioneered the BioBrace implant, a breakthrough biocomposite scaffold featuring a highly porous collagen matrix that is reinforced with bioresorbable microfilaments. The BioBrace implant is intended to reinforce soft tissue repairs in several clinical applications and is cleared by the U.S. Food and Drug Administration under K203267.
Brian K. Hutchison, Chair and CEO
Ryan Bosco, Controller
Catalyst OrthoScience Inc., a medical device company focused on the upper extremity orthopedics market, is disrupting the usual approaches to shoulder replacement surgery. Catalyst’s ArcherTM CSR Total Shoulder System is a unique single-tray, bone-preserving arthroplasty system, offering precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. The ArcherTM R1 Reverse Shoulder System is a single-tray arthroplasty system that offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants. The company recently introduced its ArcherTM 3D Targeting imaging software for its current product offerings. Headquartered in Naples, Fla., Catalyst products are available across the U.S.
Ted Bird, Chief Strategy Officer
Jeff Bennett, President and COO
Dymicron is advancing a next generation total disc replacement system for the cervical spine – Triadyme-C™, made from polycrystalline diamond – one of the strongest substances known to man. Triadyme-C emulates the complex coupled motion of a natural spinal disc while providing stability throughout the range of motion. The exceptional durability of polycrystalline diamond virtually eliminates the risks of wear debris for the lifetime of the patient.
Kyle Rose, Managing Director
Kyle Rose has been a member of Canaccord Genuity’s medical technology research team since 2010 and is the senior analyst responsible for covering the orthopedics, diabetes, aesthetics and ENT sectors. Prior to joining Canaccord Genuity, Kyle worked as an associate product manager for Zimmer Biomet (formerly Biomet Microfixation), a medical device manufacturer focusing on the craniomaxillofacial, neurosurgery, and cardiothoracic markets. Kyle holds an MBA from the Kellogg School of Management at Northwestern University as well as a BA from the University of Michigan.
Dennis O’Dowd, CEO
Suzanne Maher, PhD – Co-Founder
Tony Chen, PhD – Director of Scientific Affairs
AGelity Biomechanics is a medical device company developing innovative cartilage repair products that look, feel and act like native tissues. The Company’s first product, AGelity-OCI, is targeting cartilage damage in the knee, a very large and growing market lacking a true off-the-shelf solution. AGelity is the first spin-out from the Hospital for Special Surgery (“HSS”) and has a strong technical team of clinicians, scientists, and management working together to address the lack of reliable and early stage treatments for cartilage repair in healthy adults with injury-induced osteoarthritis. The Company has been largely funded through non-dilutive extramural grants from the National Institutes of Health, including the prestigious Small Business Innovation Research Phase I and II grants. In total the Company has secured $2.2 million of non-dilutive grants and awards to fund the development of its core technology, AGelity-OCI.
IlluminOss Medical, Inc.
Bob Rabiner, Chief Technical Officer
Mike Mogul, Chairman
IlluminOss Medical, Inc. is a privately held, commercial-stage medical device company offering a unique, minimally invasive technology for the repair and stabilization of fractures in poor quality weakened bone; particularly applicable for osteoporotic and pathologically compromised bone. The IlluminOss system utilizes a light-curable liquid monomer which is infused and contained within a conformal balloon sized to the patient’s anatomy and then illuminated with visible blue light converting the liquid to a strong hardened polymer, creating a patient-conforming intramedullary implant. The cured implant conforms to the shape of the patient’s intramedullary canal, providing rapid strength and stability to the compromised bone. Designed as a stand-alone implant, however should supplemental fixation devices be needed, they can be placed anywhere along the implant. The speed, simplicity and minimally invasive procedure has permitted the majority of patients treated with IlluminOss to return to their daily living activities far sooner and with less use of post-operative pain medications. Used in over 4000 patients in Europe, IlluminOss has been recently launched in the United States for general trauma use. The IlluminOss system is both FDA-cleared and CE marked for a wide variety of anatomical sites, with further indications pending. IlluminOss is headquartered in East Providence, RI.
Bryan Lord, Co-Founder, CEO
Dave Carey, Chief Commercial Officer
Pristine Surgical is dedicated to improving the surgical episode for patient, surgeon and center in endoscopic procedures via our single-use digital visualization platform. We provide consistently clear images with a brand-new endoscope, every time.
Richard Treadwell, President & CEO
Louie Fielding, COO and co-founder
Richard is an accomplished senior executive with more than 25 years of operating experience and a deep understanding of general management in healthcare. He has held functional leadership roles in marketing, business development, engineering and product development. As a founder of two Bay Area-based startups, he has demonstrated entrepreneurial acumen with fundraising, P&L and operating leadership. Richard has achieved consistent excellent results across a broad range of medical device therapeutic areas, including interventional cardiology at Biosensors International, cardiac surgery at Embol-X, pulse-oximetry at Nellcor, orthodontic support at Align Technology/General Orthodontic and otolaryngology at Aardvark Medical. Richard holds an MBA from The Wharton School at the University of Pennsylvania, as well as an MA in International Relations from the Johns Hopkins School of Advanced International Studies (SAIS) and a BS from Stanford University in Engineering (Product Design).